DUBLIN, Sept. 24, 2021 /PRNewswire/ — The “Global Proteomics Partnering Terms and Agreements 2010 to 2021” report has been added to ResearchAndMarkets.com’s offering.
The Global Proteomics Partnering Terms and Agreements 2010 to 2021 report provides an understanding and access to the Proteomics partnering deals and agreements entered into by the worlds leading healthcare companies.
- Trends in Proteomics partnering deals
- Disclosed headlines, upfronts, milestones and royalties by stage of development
- Proteomics partnering contract documents
- Top Proteomics deals by value
The Global Proteomics Partnering Terms and Agreements report provides an understanding and access to the Proteomics partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter Proteomics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Proteomics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains links to online copies of actual Proteomics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
For example, analyzing actual company deals and agreements allows assessment of the following:
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What are the precise rights granted or optioned?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Report Scope
Global Proteomics Partnering Terms and Agreements 2010 to 2021 is intended to provide the reader with an in-depth understanding and access to Proteomics trends and structure of deals entered into by leading companies worldwide.
Global Proteomics Partnering Terms and Agreements 2010 to 2021 includes:
- Trends in Proteomics dealmaking in the biopharma industry since 2010
- Analysis of Proteomics deal structure
- Access to headline, upfront, milestone and royalty data
- Access to over 550 Proteomics deal records and contract documents where available
- The leading antibody deals by value since 2010
- Most active Proteomics dealmakers since 2010
- The leading Proteomics partnering resources
In Global Proteomics Partnering Terms and Agreements 2010 to 2021, the available contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy and technology target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Executive Summary:
Global Proteomics Partnering Terms and Agreements 2014 to 2019 provides the reader with the following key benefits:
- In-depth understanding of Proteomics deal trends since 2014
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of Proteomics agreements with numerous real life case studies
- Comprehensive access to Proteomics deals entered into by the world’s biopharma companies, together with real world clause examples and contracts where available
- Full listing of Proteomics deals by company A-Z, deal value, phase of development, deal type, and therapy focus
- Identify leading Proteomics deals by value since 2014
- Identify the most active Proteomics dealmakers since 2014
- Detailed access to actual Proteomics contracts enter into by the leading fifty big pharma and big biotech companies
- Insight into the terms included in a Proteomics agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Key Topics Covered:
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in Proteomics dealmaking
2.1. Introduction
2.2. Proteomics partnering over the years
2.3. Most active Proteomics dealmakers
2.4. Proteomics partnering by deal type
2.5. Proteomics partnering by therapy area
2.6. Deal terms for Proteomics partnering
2.6.1 Proteomics partnering headline values
2.6.2 Proteomics deal upfront payments
2.6.3 Proteomics deal milestone payments
2.6.4 Proteomics royalty rates
Chapter 3 – Leading Proteomics deals
3.1. Introduction
3.2. Top Proteomics deals by value
Chapter 4 – Most active Proteomics dealmakers
4.1. Introduction
4.2. Most active Proteomics dealmakers
4.3. Most active Proteomics partnering company profiles
Chapter 5 – Proteomics contracts dealmaking directory
5.1. Introduction
5.2. Proteomics contracts dealmaking directory
Chapter 6 – Proteomics dealmaking by technology type
Chapter 7 – Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendices
For more information about this report visit https://www.researchandmarkets.com/r/6r4su2
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Related Links
http://www.researchandmarkets.com
PlatoAi. Web3 Reimagined. Data Intelligence Amplified.
Click here to access.
